Reference

1. Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods FERENCES and major patterns in GLOBOCAN 2012. Int J Cancer 2015;136:E359–E386.
2. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer. 2013;49:1374–1403.
3. Gilman, A. Symposium on advances in pharmacology resulting from war research: Therapeutic applications of chemical warfare agents. Fed. Proc. 1946, 5, 285-292.
4. Goodman, L.S.; Wintrobe, M.M.; Dameshek, W.; Goodman, M.J.; Gilman, A.; McLennan, M.T. Nitrogen mustard therapy: Use of methyl-bis (h-chloroethyl) amine hydrochloride and tris (h- chloroethyl) amine hydrochloride for Hodgkin’s disease, lymphosarcoma, leukemia, and certain allied and miscellaneous disorders. JAMA 1946, 132, 126-132.
5. Farber, S.; Diamond, L.K.; Mercer, R.D.; Sylvester, R.F., Jr.; Wolff, J.A. Temporary remissions in acute leukemia in children produced by folic acid antagonist, 4-aminopteroyl-glutamic acid (aminopterin). N. Engl. J. Med. 1948, 238, 787-793.
6. Hitchings, G.H.; Elion, G.B. The chemistry and biochemistry of purine analogs. Ann. N. Y. Acad. Sci. 1954, 60, 195-199.
7. Elion, G.B.; Singer, S.; Hitchings, G.H. Antagonists of nucleic acid derivatives. VIII. Synergism in combinations of biochemically related antimetabolites. J. Biol. Chem. 1954, 208, 477-488.
8. Siegel, R.L.; Miller, K.D.; Fuchs, H.E.; Jemal, A. Cancer Statistics, 2021. CA Cancer J. Clin. 2021, 71, 7–33. [Google Scholar] [CrossRef]
9. Cooper, G.M. The Cell: A Molecular Approach. In The Development and Causes of Cancer, 2nd ed.; Sinauer Associates: Sunderland, MA, USA, 2000. Available online: https://www.ncbi.nlm.nih.gov/books/NBK9963/ (accessed on 1 January 2020).
10. https://my.clevelandclinic.org/health/diseases/12194-cancer
11. Paclitaxel chemotherapy: from empiricism to amechanism-based formulation strategyCharity D Scripture, William D Figg & Alex SparreboomTo cite this article: Charity D Scripture, William D Figg & Alex Sparreboom (2005) Paclitaxelchemotherapy: from empiricism to a mechanism-based formulation strategy, Therapeuticsand Clinical Risk Management, 1:2, 107-114, DOI:10.2147/tcrm.s1210762910To link to this article: https://doi.org/10.2147/tcrm.s121076291
12. https://en.m.wikipedia.org/wiki/Paclitaxel
13. E. K. Rowinsky and R. C. Donehower, “Paclitaxel (Taxol),” The New England Journal of Medicine, vol. 332, no. 15, pp. 1004–1014, 1995.View at: Publisher Site | Google Scholar
14. J. Parness and S. B. Horwitz, “Taxol binds to polymerized tubulin in vitro,” The Journal of Cell Biology, vol. 91, no. 2, pp. 479–487, 1981. View at: Publisher Site | Google Scholar
15. https://images.app.goo.gl/KuDZNrESVMs7K8JaA
16. Mamounas E, Brown A, Fisher B et al. 3-hour(hr) high dosetaxol (T) infusion in advanced breast cancer (ABC): an NSAPB phase II study. Proc Am Soc Clin Oncol 1995;14:127.
17. Seidman AD, Tiersten A, Hudis C et al. Phase II trial of paclitaxel by 3-hour infusion as initial and salvage chemotherapyfor metastatic breast cancer. J Clin Oncol 1995;13:2575-2581.
18. Davidson NG. Single-agent paclitaxel as first-line treatment of metastatic breast cancer: the British experience. SeminOncol 1996;23(suppl 11):6-10.
19. Holmes FA, Valero V, Walters RS et al. The M.D. Anderson Cancer Center experience with taxol in metastatic breast cancer . J Natl Cancer Inst Monogr 1993;15:161_169.
20. Ovarian Cancer in Australia: An Overview, 2010. Australian InstiTute of Health and Welfare and National Breast and Ovarian CanCer Centre (Australia). Cancer SeriesCanberra,Australia: Australi- An Institute of Health and Welfare 2010, p 115-120.
21. Seidman AD, Reichman BS, Crown JP et al. Paclitaxel as second and subsequent therapy for metastatic breast cancer:activity independent of prior anthracycline response. J Clin3 Seidman AD, Tiersten A, Hudis C et al. Phase II trial of pacliOncol 1995;13:1152-1159.
22. Fountzilas G, Athanassiades A, Giannakakia T et al. A phaseII study of paclitaxel in advanced breast cancer to anthracycline.Eur J Cancer 1996;32:47-5la.
23. Kampan NC, Madondo MT, McNally OM, Quinn M, Plebanski M. Paclitaxel and its evolving role in

the management of ovarian cancer. BioMed Res Int 2015; 2015: 1-

21http://dx.doi.org/10.1155/2015/413076 PMID: 26137480

24. Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021; 71(3): 209-49
25. Akerley W III. Paclitaxel in advanced non-small cell lung cancer : An alternative high-dose weekly schedule. Chest 2000; 117(4): 152S-5S.
26. Löwe J, Li H, Downing KH, Nogales E. Refined structure of ??-Tubulin at 3.5 Å resolution edited by I. A. Wilson. J Mol Biol 2001; 313(5): 1045-57. http://dx.doi.org/10.1006/jmbi.2001.5077 PMID: 11700061
27. Zhang DY, Dmello C, Chen L, et al. Ultrasound-mediated delivery Of paclitaxel for glioma: A comparative study of distribution, toxIcity, and efficacy of albumin-bound versus Cremophor formulaTions. Clin Cancer Res 2020; 26(2): 477-86. http://dx.doi.org/10.1158/1078-0432.CCR- 19-2182 PMID:31831565
28. Löwe J, Li H, Downing KH, Nogales E. Refined structure of ??-Tubulin at 3.5 Å resolution edited by I. A. Wilson. J Mol Biol 2001; 313(5): 1045-57. http://dx.doi.org/10.1006/jmbi.2001.5077 PMID: 11700061
29. Urakami S, Igawa M, Kikuno N, et al. Combination chemotherapy With paclitaxel, estramustine and carboplatin for hormone refracto-Ry prostate cancer. J Urol 2002; 168(6): 2444-50. http://dx.doi.org/10.1016/S0022-5347(05)64164-X PMID: 12441936
30. Ma G, Liu Y, Peng C, Fang D, He B, Nie J. Paclitaxel loaded Electrospun porous nanofibers as mat potential application for Chemotherapy against prostate cancer. Carbohydr Polym 2011; 86(2): 505-12. http://dx.doi.org/10.1016/j.carbpol.2011.04.082
31. Benedetti Panici P, Palaia I, Graziano M, Bellati F, Manci N, Angioli R. Intraperitoneal paclitaxel as consolidation treatment in ovarian cancer patients: a case control study. Oncology 2010; 78(1): 20-5. http://dx.doi.org/10.1159/000287968 PMID: 20185937
32. Bae JH, Lee JM, Ryu KS, et al. Treatment of ovarian cancer with paclitaxel- or carboplatin-based intraperitoneal hyperthermic chemotherapy during secondary surgery. Gynecol Oncol 2007; 106(1): 193- 200. http://dx.doi.org/10.1016/j.ygyno.2007.03.019 PMID: 17466362.
33. D.A. Yardley, nab-Paclitaxel mechanisms of action and delivery, J Control Release, 170 (2013) 365- 372.
34. A.C. Anselmo, S. Mitragotri, Nanoparticles in the clinic, Bioengineering & Translational Medicine, 1 (2016) 10-29.
35. V.P. Torchilin, Multifunctional, stimuli-sensitive nanoparticulate systems for drug delivery, Nature reviews. Drug discovery, 13 (2014) 813-827.
36. N.I. Marupudi, J.E. Han, K.W. Li, V.M. Renard, B.M. Tyler, H. Brem, Paclitaxel: a review of adverse toxicities and novel Delivery strategies, Expert Opin Drug Saf, 6 (2007) 609-621.
37. S.C. Kim, D.W. Kim, Y.H. Shim, J.S. Bang, H.S. Oh, S.W. Kim, M.H. Seo, In vivo evaluation of polymeric micellar paclitaxel formulation: toxicity and efficacy, Journal of Controlled Release, 72 (2001) 191-202.
38. H. Gelderblom, J. Verweij, K. Nooter, A. Sparreboom, Cremophor EL: the drawbacks and advantages

of vehicle selection For drug formulation, European journal of cancer, 37 (2001) 1590-1598.

39. A. Sparreboom, L. Van Zuylen, J. Verweij, K. Mross, E. Brouwer, L. Gianni, Interrelationships of paclitaxel disposition, Infusion duration and Cremophor EL kinetics in cancer patients., Clin Cancer Res, 5 (1999) 3840s-3840s.
40. W. Lorenz, H.J. Reimann, A. Schmal, P. Dormann, B. Schwarz, E. Neugebauer, A. Doenicke, Histamine-Release in Dogs by Cremophor-El and Its Derivatives – Oxethylated Oleic-Acid Is Most Effective Constituent, Agents Actions, 7 (1977) 63-67.
41. M.R. Green, G.M. Manikhas, S. Orlov, B. Afanasyev, A.M. Makhson, P. Bhar, M.J. Hawkins, Abraxane(®), a novel Cremophor(®)-free, albumin-bound particle form of paclitaxel for the treatment of advanced non-small-cell lung cancer, Ann Oncol, 17 (2006) 1263-1268.
42. W.J. Gradishar, Albumin-bound paclitaxel: a next-generation taxane, Expert Opin Pharmaco, 7 (2006) 1041-1053.
43. K. Paal, J. Muller, L. Hegedus, High affinity binding of paclitaxel to human serum albumin, Eur J Biochem, 268 (2001) 2187-2191.
44. W.J. Gradishar, S. Tjulandin, N. Davidson, H. Shaw, N. Desai, P. Bhar, M. Hawkins, J. O’Shaughnessy, Phase III trial of Nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer, J Clin Oncol, 23 (2005) 7794-7803.
45. S. Singh, A.K. Dash, Paclitaxel in Cancer Treatment: Perspectives and Prospects of its Delivery Challenges, Crit Rev Ther Drug, 26 (2009) 333-372.
46. https://m.indiamart.com/proddetail/taxol-100-mg-injection-21409606033.html
47. https://m.indiamart.com/proddetail/abraxane-nab-paclitaxel-injection-16367577291.html
48. Q. Chen, Q.Z. Zhang, J. Liu, L.Q. Li, W.H. Zhao, Y.J. Wang, Q.H. Zhou, L. Li, [Multi-center prospective randomized trial on Paclitaxel liposome and traditional taxol in the treatment of breast cancer and non- small-cell lung cancer], Zhonghua zhong Liu za zhi [Chinese journal of oncology], 25 (2003) 190-192.
49. X. Xu, L. Wang, H.Q. Xu, X.E. Huang, Y.D. Qian, J. Xiang, Clinical Comparison between Paclitaxel Liposome (Lipusu ®) And Paclitaxel for Treatment of Patients with Metastatic Gastric Cancer, Asian Pac J Cancer P, 14 (2013) 2591-2594.
50. T.Y. Kim, D.W. Kim, J.Y. Chung, S.G. Shin, S.C. Kim, D.S. Heo, N.K. Kim, Y.J. Bang, Phase I and pharmacokinetic study of Genexol-PM, a cremophor-free, polymeric micelle-formulated paclitaxel, in patients with advanced malignancies, Clin Cancer Res, 10 (2004) 3708-3716.
51. W.T. Lim, E.H. Tan, C.K. Toh, S.W. Hee, S.S. Leong, P.C. Ang, N.S. Wong, B. Chowbay, Phase I pharmacokinetic study of a Weekly liposomal paclitaxel formulation (Genexol-PM) in patients with solid tumors, Ann Oncol, 21 (2010) 382-388.
52. K.S. Lee, H.C. Chung, S.A. Im, Y.H. Park, C.S. Kim, S.B. Kim, S.Y. Rha, M.Y. Lee, J. Ro, Multicenter phase II trial of Genexol-PM, a Cremophor-free, polymeric micelle formulation of paclitaxel, in patients with metastatic breast cancer, Breast Cancer research and treatment, 108 (2008) 241-250.
53. M.W. Saif, N.A. Podoltsev, M.S. Rubin, J.A. Figueroa, M.Y. Lee, J. Kwon, E. Rowen, J. Yu, R.O. Kerr, Phase II clinical trial of Paclitaxel loaded polymeric micelle in patients with advanced pancreatic cancer,Cancer investigation, 28 (2010) 186-194
54. T. Boulikas, M. Vougiouka, Oncol. Rep. 10 (2003) 1663.
55. D.N. Church, A. Bahl, Cancer Treat. Rev. 32 (2006) 588.
56. S. Fu, J.J. Kavanagh, W. Hu, R.C. Bast, Int. J. Gynecol. Cancer 16 (2006) 1717.
57. H. Choy, Expert Rev. Anticancer Ther. 6 (2006) 973.
58. L.M. Pasetto, M.R. D0 Andrea, A.A. Brandes, E. Rossi, S. Monfardini, Crit. Rev. Oncol. Hematol. 60 (2006) 59.
59. R.J. Knox, F. Friedlos, D.A. Lydall, J.J. Roberts, Cancer Res. 46 (1986) 1972.
60. R.N. Bose, Mini. Rev. Med. Chem. 2 (2002) 103.
61. J.C. Dabrowiak, Metals in Medicine, Wiley, Chichester, UK, 2009.
62. R.A. Alderden, M.D. Hall, T.W. Hambley, J. Chem. Educ. 83 (2006) 728.
63. W.J.F. Van der Vijgh, Clin. Pharmacokinet. 21 (1991) 242.
64. https://en.m.wikipedia.org/wiki/File:Carboplatin-skeletal.svg
65. https://www.hopkinsmedicine.org/news/newsroom/news-releases/2019/03/new-drug-combination- shows-promise-for-common-pediatric-brain-tumor
66. Brazilian Journal of Pharmaceutical Sciences vol. 50, n. 4, oct./dec., 2014 http://dx.doi.org/10.1590/S1984-82502014000400004
67. D. S. Alberts, S. Green, E. V. Hannigan, R. O’Toole, D. Stock-Novack, P. Anderson,E. A. Surwit, V. K. Malvlya, W. A. Nahhas, C. J. Jolles, J. Clin. Oncol. 1992, 10, 706.
68. .K. Swenerton, J. Jeffrey, G. Stuart, M. Roy, G. Krepart, J. Carmichael, P. Drouin, R.Stanimir, G. O’Connell, G. MacLean, J. Clin. Oncol. 1992, 10, 718.
69. A. R. MacKenzie, Cancer 1966, 19, 1369.
70. D. J. Higby, H. J. Wallace, D. J. Albert, J. F. Holland, Cancer 1974, 33, 1219.
71. P. D. Bonomi, D. M. Finkelstein, J. C. Ruckdeschel, R. H. Blum, M. D. Green, B. MaSon, R. Hahn, D. C. Tormey, J. Harris, R. Comis, J. Clin. Oncol. 1989, 7, 1602.
72. C. Pallares, M. A. Izquierdo, A. Paredes, A. Fernandez Sagarra, L. De Andres, J. J. Lopez Lopez, Cancer 1991, 68, 40.
73. G. Calais, M. Alfonsi, E. Bardet, C. Sire, H. Bourgeois, C. Bergerot, B. Rhein, J. TorTochaux, P. Oudinot, P. Maillard, A. Favre, P. H. Bertrand, Proc. Annu. Meet. Am. Soc.Clin. Oncol. 1998, 17, A1484.
74. J. Bourhis, J. P. Pignon, L. Designe, M. Luboinski, S. Guerin, C. Domenge, Proc. Annu. Meet. Am. Soc. Clin. Oncol. 1998, 17, A1486.
75. C. N. Sternberg, A. Yagoda, H. I. Scher, R. C. Watson, H. W. Herr, M. J. Morse, P. C.Sogani, E. D. Vaughan Jr., N. Bander, L. R. Weiselberg, J. Urol. 1988, 139, 461.
76. D. J. Vaughn, S. B. Malkowicz, B. Zoltick, R. Mick, P. Ramchandani, C. Holroyde, B.Armstead, K. Fox, A. Wein, J. Clin. Oncol. 1998, 16, 255.
77. Petrioli R, Frediani B, Manganelli A et al. Comparison between a cisplatin-containing regimen and a carboplatin-containing regimen for recurrent or metastatic bladder cancer patients. A randomized phase II study. Cancer 1996; 77(2): 344-51.
78. F. Panettiere, L. Leichman, E. Tilchen, T. T. Chen, Cancer Treat. Rep. 1984, 68, 1023,
79. M. Ravry , M. Moore, Clin. Oncol. 1980, 21, 353.
80. H. Bleiberg, T. Conroy, B. Paillot, A. J. Lacave, G. Blijham, J. H. Jacob, L. Bedenne,
81. W. P. McGuire III, J. Arseneau, J. A. Blessing, P. J. DiSaia, K. D. Hatch, F. T. Given Jr., N. N. Teng, W. T.Creasman, J. Clin. Oncol. 1989, 7, 1462.
82. https://m.indiamart.com/proddetail/carboplatin-injection-carboplatin-4654643333.html
83. https://tajlifesciences.com/portfolio/carboplatin-injection-bp-10mg-ml-450mg-45ml/
84. Journal of Applied Pharmaceutical Science,available online at  www.japsonline.com Stability Testing of Pharmaceutical Products ,Sanjay Bajaj, Dinesh Singla and Neha Sakhuja.
85. Bardin C, Astier A, Vulto A, et al. Guidelines for the practical stability studies of anticancer drugs: a European consensus conference. Ann Pharm Franc¸ aises 2011; 69: 221–231.
86. Kaiser J and Kramer I. Long-term stability of clofarabineinjection concentrate and diluted clofarabine infusion solution. J Oncol Pharm Practice 2012; 18: 213–221.
87. Beignen JH. Home-based chemotherapy confronts pharmacist with stability and compatibility problems. Pharm Weekblad Sci Ed 1992; 14: 337.
88. Astier A. Compatibility of anticancer drug solutions With administering devices. EJHPP Pract 2008 ;14:55-56.